

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mathias LOCHER et al.

Art Unit: Not Yet Assigned

Int.'l Appl. No. PCT/EP2003/008607 (Filed August 4, 2003)

Examiner: Not Yet Assigned

Confirmation No. Not Yet Assigned

Filing Date: February 9, 2005

Atty. Docket No. 42804-212835

For: **NOVEL COMBINATION OF**  Customer No.

**GLUCOCORTICOIDS AND PDE-4** 

INHIBITORS ...

## **Information Disclosure Statement**

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).

In order to comply the duty of disclosure pursuant to 37 C.F.R. § 1.56, submitted herewith is a form listing the documents cited in the International Search report of International Application No. PCT/EP2003/008607. The relevance of each document is indicated in the International Search Report.

Copies of the documents are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

If the copies were not furnished and a copy of a cited document is desired, please inform the undersigned and a copy of the missing document will be supplied.

Applicants: Mathias LOCHER Attorney's Doc. No.: 42804-212835

In view of the above, no further statement of relevance need be given, and as all requirements of 37 C.F.R. § 1.97 and § 1.98, and all official guidelines pertaining to Information Disclosure Statements have been complied with, it is respectfully requested that the Examiner consider the cited publications and make them of record.

Respectfully submitted,

Date: 2/9/05

Ann S. Hobbs, Ph.D. Registration No. 36,830

VENABLE LLP P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000 Telefax: (202) 344-8300

DOCS#613018

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	Not Yet Assigned	
INFORMATION DISCLOSURE				Filing Date	Concurrently Herewith	
5	STATEMENT B	3Y /	APPLICANT	First Named Inventor	Dr. Mathias LOCHER et al.	
				Art Unit	N/A	
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	42804-212835	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA	US-6 251 923	06-26-2001	EMMANUEL et al.			
	AB	US-4 996 335	02-26-1991	NICHOLAS			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code³ -Number⁴-Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	ВА	DE 199 17 504 A	10-19-2000			⇈	
	BB	GB 2 079 755 A	01-27-1982				
	ВС	WO 03 039548 A	05-15-2003			1	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). Applicant of the patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	COMPTON C H et al., "Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study", July 28, 2001, pgs. 265-270, XP004297349, ISSN: 0140-6736.	
	СВ	WHITTAKER A J et al., "Inhaled steroid therapy in chronic obstructive pulmonary disease", March 2000, pgs. 104-109, XP009020341, ISSN: 1070-5287.	
	CC	HAMMERBECK D M et al., "Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroixidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models", August 2000, pgs. 317-329, XP009020362, ISSN: 0360-3997.	
	CD	TORPHY T J et al., "Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic", England 1999, pgs. 131-135, XP001155797, ISSN: 1094-5539.	
	CE	BARNES P J., "Chronic obstructive pulmonary disease: new opportunities for drug development", October 1998, pgs. 415-423, XP004156947, ISSN: 0165-6147.	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[Examiner ]	Date	
la · · · l	154.0	
Signature	Considered	
	1	

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. DOCS#612720